When Ginny Mason was diagnosed with inflammatory breast cancer in 1994, she never once heard the word “biomarker.” “Back then, all you got was ER and PR [the estrogen receptor and progesterone ...

A 69 year old female patient with cancer in the head (widest part) of the pancreas spreading to a major abdominal artery (left image). After combined chemotherapy and radiation treatment, the tumor ...

Proliferating cells, in particular tumor cells, express a dimeric isoenzyme of pyruvate kinase, termed Tumor M2 pyruvate kinase. In the last few years, much attention has been paid to this novel tumor ...

Researchers in Japan have developed a predictive model that could improve treatment decisions for advanced pancreatic cancer patients. By combining tumor marker readings with patients' genetic ...

Cancer is an umbrella term used to characterize the abnormal growth of cells in different organs and tissues. Specific cancer types are named and categorized commonly based on location, mutation, and ...

The Tumor Marker Gene Model (TMGM) is a diagnostic tool to determine if patients with pancreatic cancer are suited for post-treatment surgery. It determines how a patient’s DNA affects their tumor ...

Detection of a bowel cancer marker (CDH1) in wastewater may offer a new community-level early warning system for the disease, ...

Researchers at Academia Sinica and National Taiwan University Hospital have developed an AI-powered blood test that detects early-stage pancreatic cancer with near-perfect accuracy in validation ...

Tumor M2-PK is becoming established as a good noninvasive screening option for colorectal cancer with a reported sensitivity between 68.8 and 91.0% and an overall specificity ranging from 71.9 to 100% ...